What is Artrya Limited's primary innovation?

Artrya Limited uses AI to automate the detection of coronary artery disease through its cloud-based software, Salix. This innovation positions it at the forefront of healthcare technology.

How has Artrya Limited's stock performed recently?

Artrya Limited's stock has surged 678% over the past year, closing at A$4.71 on December 30, 2025. This growth highlights its strong market presence and investor confidence.

What are the financial challenges faced by Artrya Limited?

Artrya faces challenges such as negative EPS and ongoing losses, though its strong liquidity is evident from a high current ratio of 8.27. Profitability remains a concern.

What does Meyka AI rate AYA.AX, and what is the forecast?

Meyka AI assigns Artrya a 'B' grade with a 'HOLD' recommendation, projecting a 3-year target price of A$8.41, suggesting a potential upside of 78.51%.

What sector does Artrya Limited operate in?

Artrya Limited operates in the Healthcare sector, focusing on the Medical - Healthcare Information Services industry, offering AI solutions for coronary artery disease detection.

AU Stocks

Artrya Limited Stock Analysis: Rapid Growth and AI Potential

ByHuzaifa Zahoor December 30, 2025December 30, 2025

Artrya Limited (ASX:AYA) has been making waves in the Australian healthcare technology sector with its innovative AI-driven solutions for coronary artery disease detection. As of December 30, 2025, AYA.AX trades at A$4.71, reflecting a robust 678% increase over the past year. Let’s delve into the factors that have contributed to this remarkable performance and what the future holds for Artrya.